視網膜疾病治療市場規模、佔有率、成長分析、按疾病、按疾病類型、按治療技術、按給藥途徑、按最終用戶、按配銷通路、按地區 - 行業預測，2024-2031

2023年視網膜疾病治療市場規模為125.7億美元，從2024年的137.4億美元成長到2032年的280.8億美元，預測期間內(2025-2032)的複合年成長率為9.3%。

視網膜疾病的盛行率在全球範圍內不斷增加，影響了超過 2.53 億人，並對醫療保健系統構成了重大挑戰，尤其是隨著人口老化。 81% 的受影響者年齡超過 50 歲，預期壽命的延長導致眼部護理領域的需求不斷增加。視網膜疾病，特別是糖尿病性視網膜病變和糖尿病黃斑部水腫的發生率正在迅速增加，特別是在糖尿病盛行率不斷增加的新興國家。預計市場在預測期內將擴大，部分原因是可用於治療這些疾病的專業人員數量不斷增加。此外，到 2028 年，報銷政策的加強預計將支持與視網膜疾病治療相關的高成本，並推動市場成長。

目錄

介紹

• 研究目的
• 調查範圍
• 定義

調查方法

• 資訊採購
• 二手資料和主要資料方法
• 市場規模預測
• 市場假設與限制

執行摘要

• 全球市場展望
• 供需趨勢分析
• 按細分市場的機會分析

市場動態及展望

• 市場概況
• 市場規模
• 市場動態
  • 促進因素和機遇
  • 抑制因素和挑戰
• 波特的分析

主要市場考察

• 關鍵成功因素
• 競爭程度
• 主要投資機會
• 市場生態系統
• 市場吸引力指數（2024）
• PESTEL分析
• 總體經濟指標
• 價值鏈分析
• 價格分析

視網膜疾病治療市場規模：依疾病分類

• 市場概況
• 黃斑部病變
• 糖尿病眼科疾病
• 視網膜剝離
• 視網膜母細胞瘤
• 黃斑皺紋
• 黃斑裂孔
• 漂浮者

視網膜疾病治療市場規模：依疾病類型分類

• 市場概況
• 遺傳的
• 年齡相關

視網膜疾病治療市場規模：依治療技術分類

• 市場概況
• 雷射
• 冷凍的
• 植入
• 縮排
• 氣壓式視網膜固定術
• 鞏膜屈曲
• 玻璃體切除手術

視網膜疾病治療市場規模：依給藥途徑分類

• 市場概況
• 口服
• 局部的
• 玻璃體內
• 其他

視網膜疾病治療市場規模：依最終用戶分類

• 市場概況
• 醫院
• 門診手術中心
• 家庭保健
• 其他

視網膜疾病治療市場規模：依通路分類

• 市場概況
• 直接競標
• 醫院藥房
• 零售藥房
• 網路藥房
• 其他

視網膜疾病治療的市場規模

• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 西班牙
  • 法國
  • 英國
  • 義大利
  • 其他歐洲國家地區
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 其他亞太地區
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲地區
• 中東/非洲
  • 海灣合作理事會國家
  • 南非
  • 其他中東/非洲

競爭資訊

• 前5名企業對比
• 主要企業市場定位（2024年）
• 主要市場參與者所採取的策略
• 近期市場趨勢
• 公司市場佔有率分析（2024年）
• 主要企業簡介
  • 公司簡介
  • 產品系列分析
  • 按細分市場分類的佔有率分析
  • 收益與前一年同期比較（2022-2024）

主要企業簡介

• Regeneron Pharmaceuticals, Inc.（USA）
• Roche Holding AG（Switzerland）
• Novartis AG（Switzerland）
• Allergan（part of AbbVie）（USA）
• Bayer AG（Germany）
• Oculis（Switzerland）
• REGENXBIO Inc.（USA）
• Adverum Biotechnologies, Inc.（USA）
• Kodiak Sciences Inc.（USA）
• EyePoint Pharmaceuticals, Inc.（USA）
• Apellis Pharmaceuticals, Inc.（USA）
• Iveric Bio, Inc.（USA）（Acquired by Astellas）
• Annexon Biosciences（USA）
• Hemera Biosciences（USA）（Acquired by Roche）
• Gyroscope Therapeutics（UK）（Acquired by Novartis）
• Graybug Vision, Inc.（USA）
• Clearside Biomedical, Inc.（USA）
• Ocuphire Pharma, Inc.（USA）
• Lineage Cell Therapeutics, Inc.（USA）
• Ocugen, Inc.（USA）

結論和建議

Retinal Disease Therapeutics Market size was valued at USD 12.57 Billion in 2023 and is poised to grow from USD 13.74 Billion in 2024 to USD 28.08 Billion by 2032, growing at a CAGR of 9.3% during the forecast period (2025-2032).

The prevalence of retinal disorders is escalating globally, impacting over 253 million people and posing significant challenges for healthcare systems, particularly as the population ages. With 81% of individuals affected being over 50, the rising life expectancy is intensifying demand in the ophthalmic care sector. The incidence of retinal diseases, notably diabetic retinopathy and diabetic macular edema, is surging, especially in developing countries where diabetes rates are increasing. The market is anticipated to expand during the forecast period, driven by the growing number of specialized professionals capable of addressing these conditions. Furthermore, enhanced reimbursement policies are expected to facilitate market growth by 2028, assisting with the high costs associated with retinal disease treatments.

Top-down and bottom-up approaches were used to estimate and validate the size of the Retinal Disease Therapeutics market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Retinal Disease Therapeutics Market Segmental Analysis

Global Retinal Disease Therapeutics Market is segmented by disorder, disorder type, treatment techniques, route of administration, end-users, distribution channel and region. Based on disorder, the market is segmented into macular degeneration, diabetic eye disease, retinal detachment, retinoblastoma, macular pucker, macular hole and floaters. Based on disorder type, the market is segmented into genetic and age related. Based on treatment techniques, the market is segmented into laser, freezing, implanting, indenting, pneumatic retinopexy, scleral buckling and vitrectomy. Based on route of administration, the market is segmented into oral, topical, intravitreal and others. Based on end-users, the market is segmented into hospitals, ambulatory surgical centers, home healthcare and others. Based on distribution channel, the market is segmented into direct tender, hospital pharmacy, retail pharmacy, online pharmacy and others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Retinal Disease Therapeutics Market

The growth of the retinal disease therapeutics market is significantly influenced by the rising prevalence of eye disorders, especially in developed nations. Notably, the American Academy of Ophthalmology reported that as of 2016, around 93 million people globally were affected by diabetic retinopathy, with 4.2 million cases in the United States alone. Projections by the NCBI estimate that by 2040, Europe could see between 14.9 to 21.5 million individuals with early Age-Related Macular Degeneration (AMD) and up to 4.8 million with late-stage AMD. Efforts to raise awareness about eye health and encourage early treatment, particularly in developing regions, are expected to further propel the growth of the retinal disease therapeutics market in the upcoming years.

Restraints in the Retinal Disease Therapeutics Market

The growth of the Retinal Disease Therapeutics market faces several challenges, primarily due to the high costs associated with treatment options for retinal diseases. The financial burden of these therapies can deter patients from seeking necessary care. Furthermore, patients often report experiencing short-term side effects, as well as potential long-term issues like infections and inflammation following procedures like laser eye surgery. Surgical techniques, such as pneumatic retinopexy, carry risks, including unintended scleral perforation, which may further influence patient choices. Additionally, inadequate healthcare infrastructure in developing countries poses significant barriers to market expansion, limiting access to effective therapies.

Market Trends of the Retinal Disease Therapeutics Market

The retinal disease therapeutics market is witnessing a significant upward trend, fueled by the emergence of advanced technologies such as gene therapy. Innovations like Luxturna, targeting inherited retinal disorders through RPE65 gene mutations, exemplify the progress being made in this field. As numerous gene therapies involving recombinant viral vectors advance through clinical trials, their potential to ameliorate conditions like Leber's congenital amaurosis is garnering attention and investment. Between 2022 and 2028, this focus on high-end therapeutic solutions is expected to drive market growth, paving the way for improved treatment outcomes and enhanced quality of life for patients suffering from retinal diseases.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2024
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis

Global Retinal Disease Therapeutics Market Size by Disorder & CAGR (2025-2032)

• Market Overview
• Macular Degeneration
• Diabetic Eye Disease
• Retinal Detachment
• Retinoblastoma
• Macular Pucker
• Macular Hole
• Floaters

Global Retinal Disease Therapeutics Market Size by Disorder Type & CAGR (2025-2032)

• Market Overview
• Genetic
• Age Related

Global Retinal Disease Therapeutics Market Size by Treatment Techniques & CAGR (2025-2032)

• Market Overview
• Laser
• Freezing
• Implanting
• Indenting
• Pneumatic Retinopexy
• Scleral Buckling
• Vitrectomy

Global Retinal Disease Therapeutics Market Size by Route Of Administration & CAGR (2025-2032)

• Market Overview
• Oral
• Topical
• Intravitreal
• Others

Global Retinal Disease Therapeutics Market Size by End-Users & CAGR (2025-2032)

• Market Overview
• Hospitals
• Ambulatory Surgical Centers
• Home Healthcare
• Others

Global Retinal Disease Therapeutics Market Size by Distribution Channel & CAGR (2025-2032)

• Market Overview
• Direct Tender
• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy
• Others

Global Retinal Disease Therapeutics Market Size & CAGR (2025-2032)

• North America (Disorder, Disorder Type, Treatment Techniques, Route Of Administration, End-Users, Distribution Channel)
  • US
  • Canada
• Europe (Disorder, Disorder Type, Treatment Techniques, Route Of Administration, End-Users, Distribution Channel)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Disorder, Disorder Type, Treatment Techniques, Route Of Administration, End-Users, Distribution Channel)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Disorder, Disorder Type, Treatment Techniques, Route Of Administration, End-Users, Distribution Channel)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Disorder, Disorder Type, Treatment Techniques, Route Of Administration, End-Users, Distribution Channel)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2024
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2024
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

• Regeneron Pharmaceuticals, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Roche Holding AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Allergan (part of AbbVie) (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bayer AG (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Oculis (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• REGENXBIO Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Adverum Biotechnologies, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Kodiak Sciences Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• EyePoint Pharmaceuticals, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Apellis Pharmaceuticals, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Iveric Bio, Inc. (USA) (Acquired by Astellas)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Annexon Biosciences (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Hemera Biosciences (USA) (Acquired by Roche)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Gyroscope Therapeutics (UK) (Acquired by Novartis)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Graybug Vision, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Clearside Biomedical, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Ocuphire Pharma, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Lineage Cell Therapeutics, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Ocugen, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations